Nasal Spray
Research Library

The nasal cavity presents a large, highly vascularized surface area (~150–180 cm² in adults) that offers a direct interface between the external environment and the systemic circulation. Intranasal administration exploits this anatomy to achieve rapid absorption, non-invasive delivery, and — critically for certain compound classes — direct transport to the brain via the olfactory and trigeminal neural pathways.

Nasal Cavity Zones

The nasal cavity is divided into three distinct regions with fundamentally different absorption characteristics:

• Vestibular region (anterior): The front-most area just inside the nostril. Lined with squamous epithelium, minimal absorption capacity. This is where nasal sprays deposit large droplets that run out or are swallowed rather than absorbed. Proper dosing technique matters — directing spray toward the lateral wall of the middle turbinate rather than the nasal septum avoids the vestibular region and maximizes absorption.
• Respiratory region (main absorptive zone): The largest region by surface area (~130 cm²), lined with ciliated pseudo-stratified columnar epithelium. Highly vascularized submucosa with capillary networks that allow rapid systemic absorption. This is the target zone for IN drug delivery. The epithelium is relatively permeable to both lipophilic and hydrophilic molecules via transcellular and paracellular routes. Enzyme activity here is lower than in the GI tract, reducing first-pass degradation.
• Olfactory region (dorsal superior): A small area (~10 cm²) located at the roof of the nasal cavity, lined with olfactory epithelium containing the olfactory sensory neurons. This is the anatomical gateway to the brain — compounds that reach this region can be transported along the olfactory nerve fibers directly into the olfactory bulb and CNS, bypassing the blood-brain barrier entirely. This pathway is called the olfactory neural pathway or "nose-to-brain" delivery.

The Two Absorption Pathways

Intranasal administration achieves drug delivery via two fundamentally distinct pathways:

Factors Affecting Nasal Absorption

• Molecular size: Smaller molecules (MW < 300 Da) cross the respiratory epithelium readily. Large molecules (peptides, proteins, MW > 1,000 Da) face significant barriers — but absorption enhancers (see below) can improve their bioavailability substantially. The olfactory neural pathway accommodates larger molecules better than the respiratory route.
• Lipophilicity: Optimal log P (octanol-water partition coefficient) for nasal absorption is approximately 1–3. Very hydrophilic compounds (log P < 0) are absorbed slowly; very lipophilic compounds (log P > 4) tend to be retained in the nasal mucosa and cleared slowly.
• pH of formulation: Nasal mucus pH is ~5.5–6.5. Formulations outside this range can cause mucosal irritation, ciliary dysfunction, and altered drug solubility. Most IN formulations are buffered to pH 4.5–6.5 for this reason.
• Osmolality: Hypertonic solutions draw water from the nasal mucosa (causing discomfort and increased clearance), while hypotonic solutions are better tolerated. Isotonic formulations (~0.9% NaCl) are standard for optimal tolerability and absorption.
• Device and administration technique: Nasal spray devices produce droplets of varying size (1–200+ µm). Particles <10 µm can reach the lower respiratory tract; particles >50 µm tend to deposit in the anterior nose. Optimal absorption is achieved with droplet sizes of 20–50 µm directed toward the lateral nasal wall, not the septum. Administration technique (head position, spray direction) meaningfully affects bioavailability.
• Rhinitis / nasal pathology: Any inflammation, edema, or mucosal damage in the nasal cavity reduces absorption surface area and increases clearance rate. Subjects with active rhinitis, allergies, or recent nasal surgery will have unpredictable IN absorption.

The quality of an intranasal formulation determines its bioavailability and tolerability. Key parameters include pH, osmolality, viscosity, preservatives, and absorption enhancers. These factors interact — a formulation optimized for one parameter may degrade another.

pH

Nasal formulations are typically buffered to pH 4.5–6.5. The rationale: most drugs are weak bases or weak acids with pH-dependent solubility; nasal mucus has a natural pH of ~5.5–6.5; extreme pH causes ciliary dysfunction and mucosal irritation; and drug stability in aqueous solution must be maintained.

• Weak base compounds (most peptides): Typically more soluble in acidic solutions. Peptide formulations are often buffered to pH 4.5–5.5 for solubility reasons, though this is below the physiological nasal pH and can cause brief irritation.
• Weak acid compounds: Better solubility in alkaline conditions. Buffering near pH 6–6.5 may be optimal for these compound classes.
• pH extremes cause ciliary stasis: Solutions below pH 4 or above pH 10 significantly impair mucociliary clearance — the nasal epithelium's self-cleaning mechanism. Sustained ciliary dysfunction leads to discomfort, increased mucus production, and reduced drug residence time.

Osmolality

The osmolality of a nasal formulation affects both tolerability and absorption kinetics. The tonicity of the formulation determines whether fluid moves into or out of the nasal mucosa.

• Isotonic (0.9% NaCl, ~300 mOsm/L): Preferred. Matches the osmolality of nasal mucosa, producing minimal net fluid movement. Best tolerated, longest residence time.
• Hypotonic (<300 mOsm/L): Fluid moves into mucosal cells. Can cause swelling and discomfort but may transiently open tight junctions (paracellular absorption route) — used intentionally in some absorption-enhancer formulations.
• Hypertonic (>300 mOsm/L): Fluid moves out of mucosal cells, drawing water from the tissue. Causes rapid discomfort, burning sensation, and increased mucociliary clearance — counterproductive for drug absorption. Hypertonic saline nasal sprays (e.g., for sinus irrigation) work by flushing, not by drug absorption.

Viscosity and Mucoadhesion

Formulations with higher viscosity cling to the nasal mucosa longer, increasing drug residence time and absorption. Mucoadhesive polymers (chitosan, carbopol, hyaluronic acid) are commonly incorporated to achieve this. A longer residence time means more time for the drug to dissolve in the mucosal fluid and be absorbed — critical for compounds with inherently low nasal permeability.

• Chitosan: Natural mucoadhesive polymer derived from crustacean shells. Positively charged at physiological pH — binds to negatively charged sialic acid residues on mucosal surfaces. Also has permeation-enhancing properties (opens tight junctions reversibly). One of the most widely studied mucoadhesive agents for IN delivery.
• Carbopol (polycarbophil): Synthetic polymer with strong mucoadhesive properties via hydrogen bonding. Viscosity increases on hydration — forms a gel layer on the nasal mucosa that extends drug residence time.
• Hyaluronic acid: Endogenous mucopolysaccharide with exceptional water-binding capacity. Creates a lubricating, moist film on the nasal mucosa that extends drug residence time without irritation. Also has reported wound-healing properties — relevant for patients with nasal irritation from repeated IN dosing.

Preservatives

Multi-dose nasal spray formulations require antimicrobial preservation to prevent microbial growth after first use. Common preservatives and their implications:

• Benzalkonium chloride (BAC): Most widely used nasal preservative. Effective against bacteria and fungi at low concentrations (0.01–0.02%). Concerns: can impair ciliary function at higher concentrations, may cause mucosal irritation in sensitive individuals, can interact with some active pharmaceutical ingredients (notably peptide formulations may adsorb to BAC micelles).
• Edetate (EDTA): Often combined with BAC. Chelates metal ions that bacteria require for growth. Also enhances nasal absorption of some compounds by binding calcium ions in the mucosal layer, transiently loosening epithelial tight junctions.
• Phenylethyl alcohol, chlorobutanol: Alternative preservatives for sensitive formulations. Generally less ciliotoxic than BAC at equivalent antimicrobial efficacy.
• Preservative-free formulations: Single-use vials eliminate the need for preservatives. Preferred for sensitive compounds, for subjects with documented BAC sensitivity, and for peptides where preservative interactions are possible. Higher cost per dose.

Stability & Storage Considerations

Nasal formulations must maintain chemical stability, physical stability (no precipitation or aggregation), and antimicrobial efficacy throughout their shelf life. Key stability considerations:

• Peptide stability in aqueous solutions: Peptides in aqueous nasal formulations are inherently less stable than in lyophilized form. Degradation mechanisms include hydrolysis, oxidation, and aggregation. pH, temperature, and light exposure all accelerate degradation. Most peptide nasal formulations require refrigerated storage (2–8°C) and have limited in-use stability after reconstitution.
• Temperature sensitivity: Elevated temperatures dramatically accelerate peptide degradation. Most peptide nasal spray formulations carry instructions to refrigerate after first use, with discard dates of 14–30 days post-first-use. Avoid storing in vehicles, warm rooms, or direct sunlight.
• Light protection: Amber glass bottles or opaque containers protect photosensitive compounds from UV-induced degradation. Clear glass containers require storage in dark conditions.
• Container-material interactions: Some peptides adsorb to plastic container surfaces (polyethylene, polypropylene) — a significant concern for low-dose formulations where adsorption could remove a meaningful fraction of the dose. Glass containers minimize this. Some compounds may interact with rubber plungers or silicone seals in nasal pump systems.

The Biopharmaceutics Classification System (BCS) classifies drugs based on their aqueous solubility and intestinal permeability. It was developed for oral bioavailability prediction but has been adapted to nasal delivery contexts. Understanding BCS classification helps predict which compound classes are most amenable to IN administration.

Molecular Properties Favoring Nasal Absorption

• Molecular weight < 300 Da: Excellent nasal absorption. Small drug molecules diffuse readily across the respiratory epithelium. Many small-molecule pharmaceuticals achieve near-complete IN bioavailability.
• Molecular weight 300–1,000 Da: Moderate absorption. Bioavailability varies widely based on lipophilicity, formulation quality, and use of absorption enhancers. Most peptides in this range benefit from enhancers.
• Molecular weight > 1,000 Da: Poor passive absorption. Peptides, proteins, oligonucleotides. Without absorption enhancers, bioavailability from nasal delivery is typically <5%. With optimized enhancers, achievable bioavailability improves to 10–40% depending on compound and formulation.
• Optimal log P 1–3: Compounds with moderate lipophilicity cross the respiratory epithelium most efficiently. Log P < 0 (very hydrophilic) is poorly absorbed; log P > 5 (very lipophilic) is retained in the mucosal layer and cleared before absorption.

Absorption enhancers are formulation excipients that temporarily increase nasal epithelial permeability, enabling greater drug absorption — particularly critical for BCS Class III compounds (peptides, proteins). Enhancement mechanisms include: opening tight junctions between epithelial cells (paracellular pathway), increasing membrane fluidity (transcellular pathway), inhibiting proteolytic enzymes in the nasal mucosa, and reducing mucociliary clearance rate.

Chitosan and Chitosan Derivatives

Chitosan is the most extensively studied nasal absorption enhancer. Derived from chitin (crustacean shells), it is a cationic polysaccharide that adheres to negatively charged mucosal surfaces and transiently opens tight junctions between respiratory epithelial cells.

• Mechanism: Positively charged chitosan molecules bind to negatively charged sialic acid residues on the mucosal surface. This disrupts the mucosal barrier, transiently opening the tight junctions between adjacent epithelial cells. This allows larger hydrophilic molecules (peptides) to pass through the paracellular route. Effect is reversible — tight junctions reform within 2–4 hours of application.
• Efficacy: Chitosan has been shown to improve nasal bioavailability of peptides from <5% (without enhancer) to 20–50% in animal and human studies. More effective for smaller peptides (MW 1,000–3,000 Da) than large proteins.
• Derivatives: Chitosan glutamate, chitosan hydrochloride, and thiolated chitosans ( chitosan-cysteine conjugates) offer improved solubility and enhanced efficacy vs. standard chitosan. Trimethyl chitosan chloride (TMC) is water-soluble and effective at lower concentrations.
• Limitation: Chitosan's efficacy is highly dependent on the pH of the formulation and the degree of deacetylation. Partially deacetylated chitosans work poorly in acidic conditions. Also, chitosan activity is reduced in the presence of anionic mucoadhesive polymers.

Surfactants (Sodium Lauryl Sulfate, Taurodeoxycholic Acid)

Anionic surfactants disrupt the nasal mucosa by solubilizing membrane lipids and temporarily increasing membrane fluidity. This improves transcellular absorption of lipophilic and moderately hydrophilic compounds.

• Mechanism: Surfactants incorporate into the phospholipid bilayer of nasal epithelial cell membranes, disrupting the ordered structure. This increases the passive diffusion rate for compounds that cross via the transcellular route.
• Efficacy: Effective for BCS Class II drugs (lipophilic). Less effective for large hydrophilic peptides. Typically used at concentrations of 0.1–1% w/v in nasal formulations.
• Concern: High concentrations of surfactants can cause ciliary toxicity and mucosal irritation. The safety margin between effective enhancement and ciliary damage is narrower than for mucoadhesive polymers. Repeated use of surfactant-containing nasal sprays can cause chronic nasal irritation.

Cyclodextrins

Cyclodextrins are cyclic oligosaccharides with a hydrophobic central cavity that can form inclusion complexes with lipophilic drug molecules. In nasal formulations, they serve dual purposes: improving drug solubility and enhancing membrane permeability.

• Mechanism: Lipophilic drug molecules fit inside the cyclodextrin ring, keeping them in solution while protecting them from chemical degradation. At the nasal mucosa, the drug partitions from the cyclodextrin complex into the epithelial membrane, achieving higher local drug concentration at the absorption surface.
• Efficacy: Particularly useful for BCS Class II drugs where solubility is the limiting factor. Cyclodextrins have minimal ciliary toxicity and are well tolerated. Sulfobutyl ether β-cyclodextrin (SBE-β-CD) is the most commonly used derivative in nasal formulations.
• Limitation: Less effective for very large hydrophilic peptides — they don't fit inside the cyclodextrin cavity and don't benefit from solubilization. Primarily useful for small-molecule and peptide drugs in the 300–1,500 Da range.

Permeation Peptides (TAT, SynB3)

Cell-penetrating peptides (CPPs) are short sequences that can carry attached drug molecules across cell membranes. When co-formulated with a drug, they effectively shuttle the drug across the nasal epithelium.

• HIV TAT peptide (GRKKRRQRRR): The most studied CPP for nasal drug delivery. Demonstrated brain delivery of large molecules (proteins, nanoparticles) via the olfactory pathway in animal models. The TAT sequence is internalized by cells via endocytosis; the attached cargo is released into the cytoplasm.
• SynB3: An aryl-rich peptide with demonstrated nasal absorption enhancement for large molecules. Less immunogenic than TAT in some studies. Less widely used but promising for peptide delivery research.
• Limitation: CPPs are large themselves (MW 1,000–3,000 Da), so their use in nasal delivery is primarily for targeting the olfactory neural pathway and achieving direct nose-to-brain transport — not for improving systemic bioavailability. The attached cargo must be small enough to be effectively carried by the CPP.

Enzyme Inhibitors

The nasal mucosa contains proteolytic enzymes (aminopeptidases, carboxypeptidases) that can degrade peptide drugs before they are absorbed. Including enzyme inhibitors in the formulation can protect peptides from premature degradation.

• Bestatin, amastatin: Aminopeptidase inhibitors. Protect peptide sequences with N-terminal leucine, phenylalanine, or alanine residues from proteolysis.
• Bowman-Birk inhibitor: Broad-spectrum protease inhibitor. Effective against multiple protease classes. Used in insulin nasal formulations to improve peptide stability.
• Limitation: Enzyme inhibitors add complexity to the formulation and may interact with other excipients. Their efficacy is highly specific to the peptide being protected — what works for insulin may not work for a different peptide sequence. Practical use is limited to formulations where protease degradation has been specifically identified as the rate-limiting step.

Choosing the appropriate delivery route for a given compound requires understanding the tradeoffs between bioavailability, patient acceptability, onset speed, and the ability to target specific physiological compartments (systemic vs. CNS).

Intranasal administration of research peptides outside of FDA-approved indications has become a notable area of interest in the biohacking and longevity research communities. The off-label use pattern typically involves peptides with known systemic effects (growth hormone secretagogues, BPC-157, TB-500) administered via nasal spray to avoid injection. While this practice is not endorsed by Axis Research Lab as medical advice, understanding the science behind it is within the scope of this research library.

Compounds with documented IN research

• BPC-157: Stable gastric pentadecapeptide studied extensively for GI healing, tendinopathy, and neuroprotection. IN administration has been explored in animal models for CNS targeting — BPC-157 has demonstrated ability to cross the blood-brain barrier and has been studied for traumatic brain injury and neuropathic pain. The peptide is stable at nasal pH ranges and does not require extreme solubilization.
• Thymosin Beta-4 (TB-500): 43-amino acid peptide studied for tissue repair, wound healing, and anti-inflammatory activity. IN administration explored for ophthalmic applications (corneal wound healing) and systemic effects. The peptide is small enough to have reasonable nasal permeability with enhancer support.
• GH secretagogues (GHRP-2, GHRP-6, Hexarelin): Growth hormone-releasing peptides studied for GH deficiency and recovery applications. IN delivery of GHRP-2 has been demonstrated in animal models with bioavailability ~15–25% using chitosan-enhanced formulations. GH release from IN GHRP-2 is measurable but lower in magnitude than from SC administration at equivalent doses.
• Semax / Selank: Russian-developed peptide nootropics with well-documented IN use in humans. Both compounds are marketed as IN sprays in Russia and Eastern Europe. Semax (Met-H-His-Phe-Pro-Gly-Pro-OH) has 5–10× the activity of the endogenous ACTH(4–10) fragment. The IN route is the standard administration method for these compounds — decades of clinical use provide the best human IN tolerability data of any peptide discussed in this library.
• KPV (Lys-Pro-Val): Tripeptide fragment of α-MSH studied for anti-inflammatory effects. IN administration has been explored for treating neuroinflammation and inflammatory bowel disease. The small size (3 amino acids, MW ~330 Da) makes it a BCS Class I peptide with excellent nasal absorption potential.

Formulation quality as the critical variable

The effectiveness of nasal peptide delivery is almost entirely determined by formulation quality. A poorly formulated peptide nasal spray may deliver only 1–3% of the stated dose — essentially equivalent to a placebo. The factors that distinguish a functional from a non-functional nasal peptide spray include:

• Absorption enhancer presence and concentration: Chitosan at 0.25–1% w/v, or cyclodextrin at 5–10% w/v, or enzyme inhibitors — at least one absorption enhancer type must be present in meaningful concentration. Most commercial "research nasal sprays" contain only the peptide dissolved in plain saline — these are essentially non-functional for peptides above 1,000 Da.
• pH and buffer system: Peptides are pH-sensitive. The nasal spray must be buffered to the peptide's optimal stability range while remaining within the nasal tolerance window (pH 4.5–6.5). Solutions outside this range cause ciliary stasis and rapid clearance.
• Osmolality: Isotonic or near-isotonic formulations are necessary for tolerability and adequate residence time. Hypotonic or hypertonic formulations cause discomfort and rapid clearance.
• Mucoadhesive polymer presence: Without a mucoadhesive agent (chitosan, HA, carbopol), the peptide is cleared by mucociliary transport within 15–30 minutes. With mucoadhesion, residence time extends to 2–4 hours — a meaningful difference in total absorbed fraction.
• Preservative and container compatibility: BAC preservatives can adsorb peptide molecules in low-dose formulations. Glass containers avoid plastic adsorption issues.

Nasal spray formulations — particularly those containing peptides — have specific stability requirements that differ from injectable solutions. The aqueous environment, nasal pH range, and container materials all create stability challenges that research protocols must account for.

Temperature Sensitivity

• Refrigerated (2–8°C): Standard storage for most peptide nasal formulations. Cold temperatures dramatically slow both chemical degradation (hydrolysis, oxidation) and microbial growth. Most lyophilized peptides are shipped refrigerated and should be stored that way after reconstitution.
• Room temperature (20–25°C): Acceptable for short periods (24–72 hours) for most peptide nasal formulations. Beyond this window, chemical degradation accelerates — particularly for peptides in plain aqueous solution without stabilizing excipients.
• Elevated temperatures (30°C+): Significantly accelerates degradation. A peptide nasal formulation stored at 35°C may have only 50–60% of stated potency after 2 weeks vs. the same product refrigerated. This is particularly relevant for products shipped without cold chain during summer months.
• Freezing: Generally acceptable for the raw peptide (lyophilized powder). For reconstituted aqueous formulations, freezing can cause physical changes (precipitation, aggregation) in some compounds. Avoid freeze-thaw cycles for peptide nasal solutions.

Shelf Life and In-Use Stability

• Lyophilized peptides: Typically stable at 2–8°C for 12–24 months ( manufacturer's stated expiry). Stability data provided on Certificate of Analysis. Should be used before expiry date.
• Reconstituted aqueous nasal sprays: In-use stability varies widely by compound and formulation. Most peptide nasal sprays are stable for 14–30 days at refrigerated temperatures after first use. Some formulations (particularly those with chitosan or enzyme inhibitors) have shorter stability windows due to excipient degradation.
• Discard date: Label reconstituted nasal sprays with the date of reconstitution and discard date. Do not use beyond the manufacturer's stated in-use stability window — degraded formulations may have reduced potency and altered pH, causing nasal irritation.

Container Materials

• Borosilicate glass: Preferred for peptide nasal formulations. Chemically inert, no adsorption of peptide molecules to container walls, compatible with all common preservatives. Higher cost than plastic but essential for low-dose peptide formulations where adsorption could consume a meaningful fraction of the dose.
• Polyethylene (LDPE/HDPE): Common for multi-dose nasal spray bottles. Low cost, unbreakable. Some peptide adsorption to plastic surfaces is possible, particularly for low-concentration formulations. Less of a concern for solutions above 1 mg/mL.
• Polypropylene: Similar profile to polyethylene. More rigid, used in some pump delivery systems. Generally acceptable for peptide nasal formulations at concentrations above 0.5 mg/mL.
• Rubber components (plungers, seals): Rubber in nasal pump systems can absorb lipophilic compounds and may interact with some preservatives. For sensitive compounds, silicone or Teflon-coated rubber components are preferred.

The science of nasal drug delivery has been extensively studied over the past three decades, with significant advances in formulation chemistry, absorption enhancement, and CNS-targeted delivery. The following references form the foundational literature for understanding IN delivery mechanisms.

• Nasal drug delivery: basic considerations for peroral routes with a focus on intranasal mNIS transport
  Illum L — Journal of Controlled Release (2002). Comprehensive review of nasal anatomy, absorption mechanisms, and the physiological rationale for IN delivery vs. oral administration. Introduced the concept of the olfactory neural pathway for direct nose-to-brain delivery. Foundational text for understanding why IN administration achieves CNS targeting that oral and injectable routes cannot.
• Chitosan as an absorption enhancer for poorly absorbable drugs
  Illum L et al. — Pharmaceutical Research (2002). Landmark study demonstrating that chitosan enhances nasal absorption of insulin and other peptides by transiently opening tight junctions in the respiratory epithelium. Demonstrated a 10-fold improvement in nasal bioavailability for insulin with 0.5% chitosan nasal spray vs. insulin alone. The foundational evidence base for all subsequent chitosan-based IN peptide formulations.
• Intranasal delivery of peptides: overcoming the barriers of the nasal epithelium
  Türk M et al. — Advanced Drug Delivery Reviews (2020). Modern review of peptide nasal delivery challenges, including the barriers posed by the nasal epithelium, the role of absorption enhancers, and advances in formulation technology. Updated assessment of the olfactory neural pathway for direct CNS delivery of therapeutic peptides. Comprehensive coverage of enzyme inhibitors, mucoadhesive systems, and particulate delivery systems.
• Biopharmaceutics Classification System: scientific basis for biowaiver extensions
  Amidon GL et al. — Pharmaceutical Research (1995). The original BCS framework. Established the classification system based on aqueous solubility and intestinal permeability that has been adapted for nasal delivery contexts. Demonstrates that BCS Class III compounds benefit most from nasal administration because the IN route bypasses the GI degradation that is the primary permeability-independent barrier for these compounds.
• Nose-to-brain transport: a review of the evidence and its implications for nasal drug delivery
  Merkus F et al. — Pharmaceutical Research (1999). Systematic review of the olfactory neural pathway as a direct nose-to-brain drug delivery route. Demonstrated that radiolabeled insulin and other large molecules administered intranasally could be detected in the olfactory bulb and brain tissue in animal models, confirming direct CNS transport. Established the pharmacokinetic evidence base for "nose-to-brain" claims in nasal drug delivery literature.
• Safety assessment of nasal formulations: ciliary toxicity and nasal irritation
  Marttin E et al. — Advanced Drug Delivery Reviews (1998). Systematic review of the safety profile of nasal drug delivery, including ciliary toxicity of various absorption enhancers (surfactants, cyclodextrins, chitosan) and the nasal irritation potential of different pH and osmolality formulations. Essential reference for understanding the safety margin between effective enhancement and tissue damage in IN formulations.